In this sense, the recent profile of a drug panel across AML patient samples shows unexpected different sensitivity of different PARP drugs across samples, with some samples being sensitive only to rucaparib and others to olaparib [23]. The gene discussed is PARP1; the disease is acute myeloid leukemia.